UPB Upstream Bio, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 2022626 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY2.5%
TTM net income YoY-34.1%
TTM EPS YoY-128.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-6,116.0%
Net margin-5,712.3%
FCF margin—
EBITDA margin-6,108.9%
Returns
ROE-53.5%
ROA-51.5%
ROIC (approx.)-56.3%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets4.9%
Debt / equity0.00x
Current ratio20.45x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.03x
Accruals ratio1.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 |
|---|---|---|---|
| Income statement | |||
| Revenue | $2.85M | $2.37M | $2.38M |
| R&D expense | $136.81M | $62.97M | $31.80M |
| SG&A expense | $26.41M | $17.17M | $10.70M |
| Operating income | -$160.36M | -$77.76M | -$40.11M |
| Income tax | $0 | $0 | $0 |
| Net income | -$143.44M | -$62.81M | -$20.54M |
| EBITDA | -$160.17M | -$77.67M | -$40.05M |
| EPS (basic) | -2.66 | -5.58 | -12.95 |
| EPS (diluted) | -2.66 | -5.58 | -12.95 |
| Weighted avg. shares (diluted) | 53.85M | 13.68M | 2.95M |
| Balance sheet | |||
| Cash & equivalents | $101.58M | $325.89M | $25.83M |
| Short-term investments | $239.93M | $144.56M | $83.98M |
| Receivables | $668,000 | $613,000 | $98,000 |
| Current assets | $351.80M | $479.16M | $117.00M |
| PP&E, net | $559,000 | $582,000 | $159,000 |
| Goodwill | — | $0 | — |
| Total assets | $353.77M | $481.72M | $117.20M |
| Current liabilities | $13.45M | $10.74M | $6.51M |
| Total liabilities | $14.00M | $11.87M | $9.39M |
| Shareholders' equity | $339.77M | $469.85M | -$123.13M |
| Shares outstanding | 54.24M | 53.60M | 2.99M |
| Cash flow statement | |||
| Operating cash flow | -$133.28M | -$59.17M | -$37.93M |
| Capital expenditure | $165,000 | $511,000 | $144,000 |
| Free cash flow | -$133.44M | -$59.68M | -$38.07M |
| Investing cash flow | -$93.48M | -$59.48M | -$82.84M |
| Financing cash flow | $2.44M | $418.91M | $129.55M |
| Depreciation & amortization | $188,000 | $89,000 | $60,000 |
| Stock-based compensation | $10.33M | $6.00M | $3.33M |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.